Trinity Biotech (TRIB) Stock Price, News & Analysis

Company Overview

Trinity Biotech plc is a global diagnostic healthcare company headquartered in Bray, Ireland. The firm specializes in the development, manufacture and marketing of in vitro diagnostic products aimed at the detection and management of chronic and infectious diseases. Its offerings are designed to deliver timely and accurate results for a range of healthcare settings, from central laboratories to point‐of‐care environments.

The company’s product portfolio includes a comprehensive array of assays and instrumentation. In the diabetes segment, Trinity Biotech provides hemoglobin A1c analyzers and glucose monitoring systems. It also offers serological and rapid tests for celiac disease, immunoassays for infectious diseases such as HIV and hepatitis B and C, and assays targeting cardiovascular risk markers. These products are used by hospitals, reference labs and clinics to support diagnosis, treatment monitoring and epidemiological surveillance.

Trinity Biotech serves a worldwide customer base through direct sales operations in North America and Europe, together with a network of distributors in Asia Pacific, Latin America and the Middle East. Its manufacturing sites operate under internationally recognized quality standards, ensuring regulatory compliance across multiple jurisdictions. The company’s global footprint and supply chain infrastructure enable it to respond to regional healthcare needs efficiently.

Supported by an experienced leadership team, Trinity Biotech maintains collaborations with research institutions and healthcare providers to drive innovation in diagnostic testing. Ongoing investment in product development and strategic partnerships underpins the company’s commitment to addressing emerging healthcare challenges and improving patient outcomes around the world.

Key Stats

• Today's Range: $0.59 to $0.64
• 50-Day Range: $0.54 to $0.81
• 52-Week Range: $0.50 to $3.44
• Volume: 69,135 shs
• Average Volume: 212,770 shs
• Market Capitalization: $2.22 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Reduce

Trinity Biotech Stock Analysis - MarketRank™

Trinity Biotech scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Reduce

Consensus Rating

Trinity Biotech has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

Trinity Biotech has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Trinity Biotech is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Trinity Biotech is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for TRIB.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Trinity Biotech does not currently pay a dividend.

Dividend Growth

Trinity Biotech does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: N/A

News Sentiment

Trinity Biotech has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Trinity Biotech this week, compared to 1 article on an average week.

MarketBeat Follows

4 people have added Trinity Biotech to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Trinity Biotech insiders have not sold or bought any company stock.

Percentage Held by Insiders

8.20% of the stock of Trinity Biotech is held by insiders.

Percentage Held by Institutions

78.97% of the stock of Trinity Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 1/02/2026
• Today: 5/08/2026
• Next Earnings (Estimated): 5/21/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TRIB
• CIK: 888721
• Web: www.trinitybiotech.com
• Phone: (531) 276-9800
• Fax: 353-1276-9888
• Employees: 480
• Year Founded: 1992

Profitability

• EPS (Trailing Twelve Months): ($9.40)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$37.38 million
• Net Margins: -85.36%
• Pretax Margin: -84.91%
• Return on Equity: N/A
• Return on Assets: -36.62%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.25
• Quick Ratio: 0.12

Sales & Book Value

• Annual Sales: $43.78 million
• Price / Sales: 0.05
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($20.04) per share
• Price / Book: -0.03

Miscellaneous

• Outstanding Shares: 3,590,000
• Free Float: 3,297,000
• Market Cap: $2.22 million
• Optionable: Optionable
• Beta: N/A